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Abstract
Background: Tanzania is East Africa’s largest country. Although it is socially diverse, it has experienced general
political stability since independence in 1964. Despite gradual economic development and Tanzania’s status as one
of the biggest recipients of aid in Africa, health status remains poor. This paper explores Tanzania’s science-based
health innovation system, and highlights areas which can be strengthened.
Methods: Qualitative case study research methodology was used. Data were collected through reviews of
academic literature and policy documents, and through open-ended, face-to-face interviews with 52 people from
across the science-based health innovation system over two visits to Tanzania from July to October 2007.
Results and discussion: Tanzania has a rich but complex S&T governance landscape, with the public sector
driving the innovation agenda through a series of different bodies which are not well-coordinated. It has some of
the leading health research on the continent at the University of Dar es Salaam, Muhimbili University of Health and
Applied Sciences, the National Institute for Medical Research and the Ifakara Medical Institute, with strong donor
support. Tanzania has found developing an entrepreneurial culture difficult; nevertheless projects such as the
clusters initiative at the University of Dar es Salaam are encouraging low-tech innovation and overcoming
knowledge-sharing barriers. In the private sector, one generics company has developed a South-South
collaboration to enable technology transfer and hence the local production of anti-retrovirals. Local textile
company A to Z Textiles is now manufacturing 30 million insecticide impregnated bednets a year.
Conclusions: To have a coherent vision for innovation, Tanzania may wish to address some key issues:
coordination across stakeholders involved with health research, increasing graduates in health-related disciplines,
and building capabilities in biological testing, preclinical testing, formulation and standardization, and related areas
important to moving from basic research to applications. The private sector can be encouraged to innovate
through improved access to financing, and incentives for R&D. The diaspora community represents an untapped
source for partnerships and access to other developing world markets and technology. The government may wish
to set up mechanisms to encourage south-south collaborations, and to bring the public and private sector
together around specific projects to help realize the country’s innovation potential.
Background
Located on the Indian Ocean, Tanzania is East Africa’s
largest country with a population of 41.5 million [1].
Although it is socially diverse, with some 125 ethnic
groups, it has experienced uninterrupted peace and gen-
eral political stability since its independence in 1964.
With a historical legacy of socialist principles, Tanzania
has gradually undertaken economic reforms that have
increased private sector activity and opened up the
economy to global competition. Reforms have included
privatizations of state firms, on-going improvements to
Tanzania’s weak infrastructure, increased access to
information and communication technologies including
Internet broadband access through fiber-optic cable, and
increasing private sector activity in tourism, retail,
mining, transport, communication and agriculture sec-
tors. As a result, Tanzania’s GDP has grown at a rate of
more than 5% over the last five years, reaching 7.5% in
2007 [2].
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Despite these statistics Tanzania remains one of the
poorest countries in the world, with the majority of citi-
zens dependent on agriculture and engaged in small and
medium sized enterprises [3]. It is positioned 152nd on
the UNDP Human Development Index, with a per
capita GDP of $US 430 [1]. Tanzania is among the lar-
gest recipients of aid in Africa, with over 34% of the
national budget in the 2008/2009 financial year financed
through aid.
With annual per capita spending of $22 USD per per-
son on health, average life expectancy is 53 years [4].
Communicable diseases account for the majority of
Tanzania’s disease burden. HIV/AIDS is the leading
cause of mortality in the country, followed by malaria.
Tuberculosis, diarrheal diseases, and lower respiratory
infections are other common diseases. Non-communic-
able diseases such as cardiovascular disease and diabetes
still account for a small proportion of the disease bur-
den but are on the rise [4,5].
Science and technology (S&T) have long been impor-
tant in Tanzania. In 1968, it established a national
research council (Tanzania National Science Research
Council), one of the first African countries to do so. Its
first S&T policy was formulated in 1986 to determine
strategies for the application of science and technology
development, with a focus on agriculture and livestock.
In 1990 the Ministry of Science, Technology and Higher
Education was established and made responsible for
S&T policy. Tanzania has developed an extensive S&T
education system, including 44 higher education institu-
tions that offer S&T training and undertake research.
In this paper we present research on science-based
health innovation in Tanzania, including biotechnology.
By science-based health innovation, we mean technolo-
gical innovation across a spectrum of sophistication,
from vaccines, pharmaceuticals, and medical devices to
some plant medicines where attempts to scientifically
standardize or characterize medicines have been made.
We take a broad definition of innovation as not only
new-to-the-world innovation, but also the diffusion,
adaptation and use of technologies. We use the OECD
definition of biotechnology: ‘the application of science
and technology to living organisms, as well as the parts,
products and models thereof, to alter living or non-
living materials for the production of knowledge, goods
and services’ [6].
The purpose of this paper is to describe and analyze
science-based health innovation using an innovation sys-
tem framework, which takes into account the wide vari-
ety of stakeholders who contribute to the innovation
process and emphasizes the dynamic interaction and
knowledge flow between them [7]. The study was
undertaken at the invitation of the then Minister of
Science, Technology and Higher Education, who later
became the Minister of Communications, Science and
Technology. It is the first study of its kind on Tanzania
with an emphasis on commercialization and understand-
ing how knowledge translation happens in the area of
health product development.
Methods
A case study research methodology was used in this
study [8]. Data was collected through reviews of aca-
demic literature and policy documents and through
open-ended, face-to-face interviews in Tanzania. Inter-
viewees were identified through snowball and purposive
sampling. We interviewed 52 people from across the
science-based health innovation system, including gov-
ernment officials (n=16), researchers (n=22), entrepre-
neurs (n=6), international donors (n=6) and non-
governmental organization representatives (n=2), over
two visits to Tanzania from July to October 2007. Since
our initial research visits, we have continued to engage
stakeholders to address key challenges identified in this
case study.
All quotes are from the interviews unless noted, and
with permission. This study was approved by the Office
of Research Ethics of the University of Toronto.
Results and discussion
In the following sections, we describe and discuss Tan-
zania’s science-based health innovation system.
Government
In February 2008 the Ministry of Communication,
Science and Technology (MCST) was created with a
mandate to further develop policies and guidelines and
co-ordinate science, technology and innovation in Tan-
zania. S&T policies are being revised to include not only
S&T but also innovation. These reforms are being
initiated in support of the government’s Vision 2025
objective of ‘transform[ing] the economy into a strong,
resilient and competitive one, buttressed by science and
technology’ [9]. In the words of Minister Peter Msolla,
the Tanzanian Minister of Communications, Science
and Technology, to fellow ministers meeting for the
High-level Segment of the UN Economic and Social
Commission’s meeting on 1 July 2008, ‘without a dose
of innovation [in Tanzania], the macro-economic gains
achieved over the years through the implementation of
sound economic policies would be wiped out.’
Another important body in S&T development is the
Commission for Science and Technology (COSTECH), a
semi-autonomous institution under the MCST responsi-
ble for coordination and promotion of research in
Tanzania since 1986. COSTECH advises the government
on S&T, and it has eight sectoral advisory committees
including: Agriculture and Livestock, Social Sciences,
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Basic Sciences, Natural Resources, Environment,
Medicine and Health, Industry and Energy. Biotechnol-
ogy is one area of interest under basic sciences, with an
emphasis on agricultural biotechnology.
The Ministry of Health and Social Welfare is man-
dated to undertake research, policy, coordination and
regulation of health in the country. An important stated
focus of health research in the country is related to tra-
ditional medicine. The government is developing ways
to integrate traditional medicine into mainstream medi-
cine, recognizing that at least 70% of Tanzanians use
traditional medicine as the first port-of-call for primary
care – particularly those in rural areas. The Traditional
Medicines and Alternative Medicines Act guides the use
and promotion of traditional medicine in Tanzania. A
Traditional Medicines Board under the Ministry of
Health and Social Welfare has been set up to regulate
traditional medicines in the country.
The Medical Stores Department, a parastatal agency
under the Ministry, is the main procurer, supplier and
distributor of essential medicines for the public sector,
and is the primary supplier to faith based organizations
and non commercial groups providing health services in
Tanzania. The Pharmaceutical Services Unit of the
Ministry has been set up to guide the development of
the local pharmaceutical sector and to ensure the
Medical Stores Department performs according to the
MSC Act (1993). The National Medicine Policy (NMP,
1991) and Pharmaceutical Master Plan (1992-2002) are
being reviewed to reflect a shift from the push to pull
supply system and increase the promotion of the local
manufacturing sector. A critical barrier we observed was
around shortage of staff and operational capacity within
the Pharmaceutical Services Unit, along with a shortfall
of trained pharmacists in the country.
The government through COSTECH established in
2002 a multi-sectoral National Biotechnology Advisory
Committee (NBAC) with the mandate of advising the
government on all issues pertaining to the safe develop-
ment and application of biotechnology. A National
Biotechnology Policy has been drafted. The main objec-
tive of the policy is to ensure that Tanzania has the
capacity and capability to capture benefits arising from
health, agricultural, industrial and environmental appli-
cations of biotechnology, while protecting and sustaining
the safety of the community and the environment. Spe-
cific policy objectives include the development of a
coordinated biotechnology strategy; establishing bio-
safety regulations and guidelines; conserving genetic
resources; linking R&D and industrial capacity for bio-
technology in Tanzania; and a number of innovation-
related aims such as strengthening innovative financing
and intellectual property (IP) rights.
Despite the country’s significant S&T infrastructure in
both health and biotechnology, there has been a relative
lack of governmental investment in both research infra-
structure and investment in research to support the type
of innovation envisioned in governmental policies. It has
been estimated that about 0.18% of GDP is invested in
research and development (R&D) [10]. However, in
2009 the President of Tanzania announced that the gov-
ernment would increase its funding for R&D to one per
cent of GDP for the financial year 2009/2010, amount-
ing to 311 billion Tanzanian shillings (approximately US
$235 million). A recent survey of funds flowing to R&D
institutions conducted by COSTECH indicate that the
donor contribution to R&D expenditure is the largest at
52%, followed by government at 34%, and a small pro-
portion from institutions’ internally generated funds at
14% [11]. Currently there is no significant government
funding dedicated towards commercialization of innova-
tion, such as proof of concept funds or product develop-
ment funds.
The Tanzania Food and Drug Authority (TFDA)
established under the Food, Drugs, and Cosmetics Act
(2003) is the country’s key regulatory body responsible
for controlling the quality, safety and effectiveness of
food, drugs and medical devices. It is a semi- autono-
mous agency under the Ministry of Health and Social
Welfare, with 50 drug inspectors and an emphasis on a
science-based approach. With regards to regulation and
registration of clinical trials locally, there seems to be
jurisdictional overlap between the National Institute for
Medical Research’s (NIMR’s) National Health Research
Ethics Committee and TFDA. They are working
together to address this issue by forming a joint ethics
approval process. We found that the TFDA is unique as
a regulator, as it also plays a role in the promotion of
the local pharmaceutical manufacturing sector. Having
realised the need to develop the local pharmaceutical
industry, it developed a concept paper, which it
presented it to the Minister of Health. As Mrs M.N.
Sigmondo, the director general of the TFDA, explains:
“The Ministry approved the concept paper, and now we
have in place a sort of plan covering ten years – 2006 to
2016 – that tries to elaborate how best as a country we
could utilize the existing potential in the country to pro-
mote local production, including research and
development.”
The Business Registration and Licensing Agency
(BRELA) under the Ministry of Industry, Trade and
Marketing is mandated to regulate intellectual property
rights in Tanzania (except copyrights which are under
the Copyright Society of Tanzania). Most locally owned
patents are in the fields of engineering and agriculture,
with none identified in health biotechnology. Tanzania
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has been a member of the World Trade Organization
since 1995 and has thus ratified the Trade Related Intel-
lectual Property Rights (TRIPS) agreement. Due to its
classification as a Least Developed Country, it is exempt
from implementing, enforcing or applying TRIPS provi-
sions on patents with respect to pharmaceutical pro-
ducts until 1st January 2016. However, Tanzania has so
far not made much use of this exemption. The Patent
Act (1987) makes patents available for both processes
and products without expressly excluding pharmaceuti-
cal products. The Act also does not appear to have pro-
visions for data protection and exclusivity. According to
the Patent Act (1987) Section 37 (2), parallel imports
from abroad are not admitted, and, though compulsory
licensing is permitted, there are restrictions. These sti-
pulations have be critiqued elsewhere as limiting Tanza-
nia’s capacity to produce essential medicines [12,13].
The government has initiated the process of amending
the Patents Act to revise and consolidate the entire
intellectual property system including other laws such as
Trade and Service Marks Act, 1986.
We found two critical challenges with respect to intel-
lectual property protection. First is the lack of awareness
around the need for intellectual property protection
amongst the research community. COSTECH in asso-
ciation with BRELA and the World Intellectual Property
Organization have established a new unit housed within
COSTECH to address this gap. The Tanzania Intellec-
tual Property Advisory Service has been set up to
increase awareness and support around intellectual
property amongst the science community locally, though
the extent to which this has had an impact is not yet
clear. Second is the weak system of policing patents. We
came across scientists and companies who were reluc-
tant to patent their research, as it requires disclosing
confidential information and there is no strong system
to enforce the patents should they be violated. This
naturally has impacts on knowledge translation.
Research institutes and universities
There are a total of 44 higher education institutions in
Tanzania. Health and biotechnology research is primar-
ily conducted by three categories of institutions: govern-
mental health research institutes, universities (public
and private), and private health research institutes. In
2006/07 total student enrolment in both private and
public universities and university colleges and institutes
was 49,967, with public universities enrolling a total of
39,218 students or 78.4% of the total students [14].
Despite the overall increase in enrolment numbers in
tertiary education, Tanzania’s numerous strong research
institutes and universities have been struggling with
recruiting students in science and technology including
biotechnology. This is partially due to lack of new
research infrastructure and trained staff.
National Institute for Medical Research
The National Institute for Medical Research (NIMR)
plays a critical role in medical research in Tanzania.
NIMR was set up as a parastatal organization under the
Ministry of Health and Social Welfare in 1979, and is
responsible for undertaking and coordinating health
research in Tanzania. It is headquartered in Dar es Sal-
aam but has ten research stations and centers through-
out the country. Its current research priority areas are
malaria, filariasis, trypanosomiasis, onchocerciasis, schis-
tosomiasis and sexually transmitted diseases including
HIV/ AIDS.
NIMR has around 87 full-time research scientists and
34 technical staff. NIMR collaborates significantly with
other Tanzanian research organizations such as Hurbert
Kairuki Memorial University (Dar Es Salaam), and inter-
national groups such as the National Institutes of Health
(US) and University of Toronto (Canada). They have
also set up a collaborative biotechnology laboratory at
the Kilimanjaro Christian Medical Centre in Moshi
which conducts multidisciplinary research on preven-
tion, control and treatment of the three poverty related
diseases HIV/ AIDS, malaria and tuberculosis.
We found scientists at NIMR who had developed an
innovative extraction process for the active ingredient of
Artemisia annua, a plant which forms the basis of arte-
misinin compounds for the treatment of malaria and
which grows in abundance in Tanzania. However, the
process had never been commercially explored, partly
due to the reluctance of scientists to share the informa-
tion outside the institution because of the lack of IP
protection. Currently, therefore, all Tanzanian Artemisia
is farmed, dried and exported to Kenya, where it is
extracted by a Kenyan private sector company, before
being shipped to Switzerland where it is further pro-
cessed for use in the anti-malarial Coartem ® produced
by Novartis and later shipped back to Tanzania to be
sold. Little commercial value is captured locally.
University of Dar es Salaam
The University of Dar es Salaam (UDSM) is the oldest
and largest university in Tanzania. In 2008, UDSM had
5775 undergraduate students and 2552 graduate stu-
dents. The university has a biotechnology unit within its
Faculty of Science, where annually around 35 students
are trained at the undergraduate level and 10 students
at the graduate level. Health research includes the iden-
tification of antimicrobial agents from Tanzania’s
biodiversity.
Outside the biotechnology unit, there are a number of
research groups in the area of natural products and tradi-
tional medicine. For example Prof. Nkunya, a Professor of
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Chemistry at UDSM, runs a research group focused on
medicinal chemistry and traditional medicine and has
established linkages with GIBEX, an international consor-
tium on biotechnology research. They are focusing on bio-
diversity, bio-exploration and natural product research
including identifying wild mushrooms as a source of bio-
medical products. With respect to commercialization of
research, the University has developed a technology trans-
fer policy and a technology transfer office. However, to
date we did not find successful examples of significant lin-
kages with the private sector.
There is an increasing emphasis on entrepreneurship
within the university. The Faculty of Commerce and
Management has established the University of Dar es
Salaam Entrepreneurship Centre, which has been pro-
moting awareness around entrepreneurship at both the
faculty and student levels. It also plays a strong role in
incubating small businesses, and has developed a busi-
ness plan competition with support from the United
Nations Development Program.
Another example of entrepreneurial leadership is the
University of Dar es Salaam’s College of Engineering
and Technology, which has developed a “Clubs, Clusters
and Incubators” program with support from the Gatsby
Foundation, the Swedish International Development
Agency and the World Bank. The program aims at pro-
moting growth of small and medium enterprises in Tan-
zania and has links with universities in Uganda and
Mozambique [15]. Currently they have 8 cluster initia-
tives focused on technology-specific areas such as vege-
table and fruit processing, nutraceuticals, sisal, metal
works, cultural tourism, seed, seaweed and mushroom,
but none to date has focused on health and biotechnol-
ogy. The three main activities each cluster initially
undertakes includes (1) mobilization of people and
resources and analysis of activities, (2) preparation and
facilitation of implementation of short term activities,
and (3) identification and facilitation of implementation
of long-term strategic activities. The success of the pilot
clusters has resulted in plans to establish an additional
11 clusters in various areas, including health, across
Tanzania. There are transferable lessons to be learnt
from this program for other universities and research
groups, with respect to knowledge translation and com-
mercialization of local health technologies; for example,
how to effectively develop linkages among stakeholders
around the focused commercialization of locally relevant
technologies, and increasing the capabilities of local
firms.
Muhimbili University of Health and Applied Sciences
(MUHAS)
MUHAS is the country’s premier public medical univer-
sity, spinning out in 2007 from the UDSM. MUHAS has
developed not only as the key medical training
institution, but also a strong medical research center,
with strong expertise in traditional medicine, clinical
trials and diagnostics, and with strong overseas
partnerships.
For example, in the 1990s Professor Zul Premji, a
researcher at MUHAS, played a critical role in the
development of the malaria rapid diagnostic test and its
validation along with the company Beckton Dickinson.
This rapid diagnostic test is now widely used and avail-
able as a product produced by various local and interna-
tional companies. As Prof. Premji explains “I was the
first one to test the validity, sensitivity and that sort of
thing of this [rapid diagnostic] test, and then we
improved on it quite a bit. Now this test…is commer-
cially available, [and] the prices have gone down because
the volumes have increased; now you can get a test for
[less than] a dollar.” Beckton Dickinson eventually
patented and commercialized the test, but it is unclear if
Prof. Premji or Tanzania captured any of the economic
value out of its research investment in this area. As
Prof. Premji points out “In the early 90s we were still
very socialistic. So we didn’t know much about these
patency rights and all that.” Since then the university
has set up a technology transfer office to capture the
value of in-house innovation, though to date there
appear to have been no success stories.
Professor Fred Mhalu is another pioneering researcher
at MUHAS. His research also focuses on adapting point
of care diagnostics to local settings for various infectious
diseases such as malaria, HIV/ AIDS, and tuberculosis.
He also recently completed a phase I study of a multi-
gene, multi-clade HIV DNA candidate vaccine in
Tanzania as part of a long-standing Swedish-Tanzanian
collaboration. At the time of the study he was recruiting
for Phase II trials for the HIV vaccine. The vaccine
being trialed is manufactured in Sweden and the US and
takes into account local conditions, including the types
of HIV prevalent.
MUHAS houses the Institute of Traditional Medicine,
which plays an important role in traditional medicine
research in the country. The institute has a herbarium
with an inventory of over 3000 plants being used locally
in traditional medicine. It has a total of 22 staff, includ-
ing 11 academic members. It has developed reasonable
capacity in the areas of natural products chemistry and
botany but still needs to develop capacity in the area of
standardization, biological testing and preclinical drug
research. It has been working in the areas of diabetes,
benign prostatic hypertrophy, and identification of anti-
microbial agents. It has a pilot manufacturing plant
which has been producing herbal preparations including
mixtures for peptic ulcers, cough, asthma and choles-
terol since 2003. The Institute was reportedly also the
only research institute that has tried to develop linkages
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with the private sector, going as far as signing an MoU
with a local pharmaceutical manufacturer; to date, the
partnership has not translated to concrete advances.
Sokoine University of Agriculture
SUA was established in 1984 with a primary focus on
agriculture and veterinary sciences. It has around 2600
undergraduate students and 400 graduate students,
including about 30 PhD students. The University offers
an undergraduate degree in Biotechnology and Labora-
tory Sciences which has a research-intensive compo-
nent to it. Currently, the University has about 175
researchers trained at the PhD level in all fields of
agriculture, forestry and veterinary medicine. They are
establishing a Centre for Biotechnology, in collabora-
tion with the International Centre for Genetic Engi-
neering and Biotechnology (Trieste, Italy), which will
have a major focus on agricultural biotechnology.
There is significant research infrastructure geared
towards agricultural biotechnology research including a
recently developed Genomic Sciences and Bioinfor-
matics Centre. The University has also recently estab-
lished a technology transfer office to stimulate research
translation.
Ifakara Health Institute
Ifakara Health Institute (IHI) is an autonomous private,
non-for-profit organization established with support
from the Swiss Tropical Institute. It is best known for
its malaria research, but has also expanded to other
areas including TB, HIV and other communicable dis-
eases. Examples of research projects it has worked on
include the evaluation of the SPf66 vaccine for malaria
control, evaluation of insecticide treated bed nets and
evaluation of iron supplements to prevent severe anae-
mia and malaria in infants. It uses an impact-based
approach to its research, and played an instrumental
role in demonstrating chloroquine resistance in East
Africa by mapping and following mutation levels around
the country, thus contributing to information showing
that the drug was no longer effective.
There have been attempts at product development.
For example, the Institute was attempting to develop a
molluscoside from a local traditional medicine to act
against schistosomiasis-carrying snails. But the product
was not clinically efficacious, resulting in the termina-
tion of the project. Dr Mshinda, former Director of IHI
and current Director General of COSTECH, says that
the key barrier to health biotechnology development
and translation is around human resources and capital:
“I think we need to create an enabling environment for
production – first to invest in human resources, and
[then] creating an environment which would be more
conducive for the private sector to start to invest. So
you need human resources, and you need to have also
financial and human resource capital. Because the
market is there – it’s a question of seeing how one can
harness it.”
Private universities
Private higher educational institutions also play a role in
health biotechnology R&D, providing training through
their undergraduate and graduate programs for future
scientists and technologists as well as doing research.
Tumaini University along with its Kilimanjaro Christian
Medical College (KCMC) and the Mikocheni Interna-
tional University are key private universities in the
health field. KCMC has developed capabilities in health
biotechnology and clinical trials. They have a biotech-
nology laboratory in collaboration with NIMR, and a
specialized Clinical Research Centre for TB clinical trials
as part of the APRIORI program. The APRIORI pro-
gram was established at KCMC with support from the
Netherlands Organization for Scientific Research, to
conduct vaccine trials and drug trials and to develop at
the same time a community-focused integral approach
for prevention and treatment. KCMC – together with
Duke University Medical Center and Kiwakkuki, a com-
munity organization fighting HIV/AIDS – receives NIH
funding to conduct clinical research on HIV/AIDS,
malaria, tuberculosis and other infectious diseases.
Table 1 shows the variety of health-related products
and processes that are being developed within Tanza-
nian research institutions.
Private sector
The local pharmaceutical industry in Tanzania appears
still in its nascent stages with an estimated local market
value in 2007 of around US$33 million [12,16]. Addi-
tionally, there is a large market for informal traditional
medicines, which are utilized by an estimated 70% of
the population. Tanzania’s pharmaceutical industry is
serviced by local generic manufacturers, generic manu-
facturers operating globally (mainly from India and
China) and a few large multinational corporations. The
local manufacturers service approximately 30% of the
country’s market with the rest serviced by importation.
Of the local generic manufacturers Shelys Pharmaceuti-
cals and Tanzania Pharmaceutical Industries Ltd (TPI)
are the largest players, commanding 50% and 30% of the
local manufactured market share respectively. Other
manufacturers include Zenufa, Keko Pharmaceutical
Industries, Interchem Pharmaceuticals and Mansoor
Daya.
Shelys (Dar es Salaam) has over 100 products on the
market. TPI (Arusha) was a state-owned pharmaceutical
company that was privatized in 1997, and is now owned
by a group of private Tanzanian investors and the Tan-
zanian Investment Funds (with a reported 40:60 split).
Both of these firms have made significant South-South
partnerships in recent years. In 2008, Aspen Pharmacare
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of South Africa acquired a 60% stake in Shelys and its
linked organization Beta Healthcare International in
Kenya. TPI has recently started production of fixed dose
antiretroviral combination therapy with technological
assistance from Thailand, including technology transfer
around manufacturing ARVs from the Faculty of Orien-
tal Medicine at the University of Rangsit in Thailand.
Another pharmaceutical company, Zenufa, has recently
set up a new manufacturing unit and is in the process
of approvals to develop therapeutics such as anti-hista-
mines, amongst other products. Zenufa, Shelys and TPI
are all at various stages of setting up and upgrading
their manufacturing units to WHO- Good Manufactur-
ing Practices standards that would allow prequalifica-
tion. Currently Tanzania has no active pharmaceutical
ingredient manufacturer. There are numerous industry
associations that play a role in advocacy and awareness,
including the Tanzania Private Sector Foundation and
Tanzanian Association of Pharmaceutical Industry. The
key buyers for pharmaceutical products in Tanzania are
the government and donor agencies.
A noteworthy example of health product innovation
outside of pharmaceuticals is that of A to Z Textile
Mills (Arusha). A to Z Textile Mills, in partnership with
the Japanese company Sumitomo, has become the lar-
gest manufacturer of long-lasting insecticide impreg-
nated bed-nets in Africa. Pellets containing insecticide
are shipped from Japan to Arusha, where they are
melted, turned into long strings which are rolled onto
spools and then formed into nets, cut, packaged and
shipped using company owned trucks to points of distri-
bution in many African countries, particularly in East
and Central Africa. A to Z currently manufactures
about 30 million bed-nets a year, which are WHO-certi-
fied and reasonably priced. Moreover, A-Z has created
over 5000 jobs for Tanzanians. (A detailed look at A to
Z’s strategy and challenges can be found in the A to Z
paper in this BMC series).
Our interviews did not find any examples where the
local private sector, including pharmaceutical manufac-
turers, have linkages with the Tanzanian research com-
munity in the area of health and biotechnology. This
was also the case with A to Z, which only considered
foreign technologies when they were initially scoping
bednet technologies. During the same time period,
Tanzanian researchers were studying and publishing
extensively on the malaria parasite and identifying alter-
native anti-malarial compounds which may have offered
alternatives to insecticides used in the bednet.
In our study we found that a lack of shared values
between research and private enterprise, low entrepre-
neurial spirit, and lack of capital are key barriers to col-
laboration between business and science. Access to
capital was reported as a major barrier for both small
and medium enterprises and large enterprises, especially
with the high interest rates prevalent locally. There is
little access to risk capital, local or international, for
innovation in general, let alone health and biotechnol-
ogy. There has been a recent rise in Tanzanian business
competitions such as the ones run by the University of
Dar es Salaam’s Entrepreneurship Centre, and the
“Believe Begin Become” national business plan competi-
tion in collaboration with Google and Technoserve.
While these are examples of incentivizing entrepreneur-
ship, to date none has been in the medical innovation
area. In the 2008 Global Competitiveness Report,
Table 1 Products and processes being developed in Tanzanian institutions
Product Health Area Organization Description
Artemisinin extraction
Process
Malaria NIMR Developed an extraction technology that provides greater yield
and that has been validated. (No large scale pilot testing yet.)
Herbal Formulation HIV/AIDS Institute for Traditional Medicine,
Muhimbili University of Health and
Applied Sciences
Herbal alkaloid- trepenoid product made from various plants.




Institute for Traditional Medicine,
Muhimbili University of Health and
Applied Sciences
Innovative plant based product. Small sample size, placebo-
controlled, double-blind clinical trial performed: negative results
Long Lasting Insecticidal
Nets
Malaria A to Z Textiles Product on market
Antimalarial Vaccines Malaria African Malaria Network Trust Conducting clinical trials at various locations in Tanzania
Acridine Orange based
Malaria Diagnostic
Malaria Muhimbili University of Health and
Applied Sciences
Being developed in collaboration with a Japanese organization.




Malaria Muhimbili University of Health and
Applied Sciences
Running clinical trials for various artesunate combination
therapies
Fungal vector control agent Malaria Ifakara Health Institute Testing a fungus with anti – anopheles activity, in collaboration
with Imperial College U.K. Fungus is applied into cloth and
placed indoors. Doing trial to replicate, look at effectiveness,
and evaluate whether production could go to scale
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businesses ranked infrastructure and an inadequately
educated workforce as most problematic factors for
doing business in Tanzania.
NGOs and donors
Donors provide over 70% of funds for health research in
Tanzania [17]. The Swedish International Development
Agency’s Department for Research Cooperation is one
of Tanzania’s chief donors supporting science, especially
in health. Swedish support has been concentrated at the
University of Dar es Salaam and Muhimbili University
College of Health Sciences, the two key institutions
involved in research and research training at the time of
initiation of the cooperation. More recently it has also
taken on funding COSTECH to undergo an organiza-
tional review. It supports research project cooperation,
faculty support (core support), Information Communica-
tion Technology (ICT) infrastructure support, and
national access to electronic journals coordinated by the
UDSM university library. It also funds regional research
programs especially in the field of technology, and activ-
ities related to knowledge dissemination.
Other agencies such as the United States Agency for
International Development, Norwegian Agency for
Development Cooperation, the German development
agency GTZ, and the Netherlands Organization for
International Cooperation in Higher Education have
been less active in funding health research. However,
external foundations are increasingly active in funding
health research in Tanzania. From 2006 to 2008 founda-
tions such as the Bill & Melinda Gates Foundation,
Comic Relief, the Rockefeller Foundation, and the Well-
come Trust provided at least US$16.7 million in direct
funding to Tanzanian institutions for health research,
with another US$24.8 million in indirect funding.
Given the heavy reliance on donor funding for health
research, local researchers were said to focus on areas
outlined by the various agencies, whose agendas are
cyclical. This results in researchers constantly changing
research interests or focus to align with available fund-
ing. As Prof. A.E. Pereka, Deputy Vice-Chancellor of
Sokoine University of Agriculture points out: “Scientists’
research is skewed to donor interest; very often we are
caught up in a scenario where we are told this type of
research is not very relevant to Africa, because they
want to fund projects which they think make a change”.
Tanzania has numerous NGOs working in the area of
health research and capacity building, such as the Afri-
can Medical and Research Foundation, a multi- country
African NGO focused on health research; and the
African Malaria Network Trust (AMANET), which pro-
motes capacity strengthening and networking of malaria
R&D in Africa. This latter organization is led by the for-
mer Director General of NIMR, Dr Wen Kilama, who
points out the importance of African-focused and Afri-
can-led research: “If you think malaria research is
expensive, try malaria”. The network supports various
activities including training, capacity strengthening for
vaccine clinical trials, and awareness of African malaria
research. AMANET is currently in the process of pro-
duct development of three vaccine candidates for
malaria: MSP 3LSP (Merozoite Surface Protein / Long
Synthetic peptide), AMA1 (Apical Membrane Antigen)
and GMZ2 (Recombinant hybrid of Glutamate Rich pro-
tein and MSP 3); it is conducting research and clinical
trials across Africa, including in Tanzania. It also con-
ducts workshops in Good Clinical Practice and provides
financial support to build local research capacity
Conclusions
Strengths and good practices
Tanzania has set up a relatively extensive S&T system
with its numerous institution and organizations, both
public and private, dedicated to various aspects of
sciences and health. There is strong political will
towards harnessing local science innovation to address
local socioeconomic needs. This is seen through the
establishment of a newly dedicated Ministry of Science,
Technology and Communication, recent STI policy
reform, and the announcement of an increase in govern-
mental funding for scientific R&D from 0.18% to 1% of
its GDP, six years ahead of schedule. The reform may
provide a policy framework to bring together elements
of the existing science and technology innovation (STI)
system, and the policy impetus to push towards innova-
tion and commercialization of health research that has
so far been missing. Tanzania’s food and drugs regula-
tory system is a leader in the region, showing leadership
in stimulating a strong local pharmaceutical manufac-
turing industry. We also found that Tanzania has a
strong research base in the areas of traditional medi-
cines and diagnostics, increasing capacity in clinical trial
research across various institutes such as KCMC,
MUHAS, and NIMR.
An exemplar of a model that facilitates commercializa-
tion of innovation is the College of Engineering and
Technology’s “Clubs, Clusters and Incubators Program”
at UDSM. The college spearheaded this initiative of
establishing innovation systems and clusters to fast track
socioeconomic development in the East African region
by harnessing local technologies and entrepreneurship.
This program has been successful in terms of develop-
ing and translating locally relevant technologies, as well
as training for entrepreneurs and establishing linkages
between public and private sector partners. The cluster
initiatives also provide an effective mechanism to pro-
mote innovation and firm competitiveness in target
technological areas of local importance such as
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nutraceuticals, along with opportunities for joint pro-
duction, research, lobbying and upgrading human
resources. The expansion from its original 8 clusters in
Tanzania to 19, along with 7 others in collaboration
with Makerere University in Uganda and some in
Mozambique, attest to its relevance to African countries
more widely.
Recommendations
Tanzania’s health innovation landscape has a large num-
ber of institution and organizations both public and pri-
vate, dedicated to various aspects of sciences and health.
In order to have a coherent vision for innovation for
development in general and for health in particular,
Tanzania may wish to address some key issues.
Like most in the region, universities and research
institutes in Tanzania continue to face infrastructure
restrictions including access to basic amenities such as
water and electricity; and these same infrastructural
challenges result in increased manufacturing costs for
the local private sector. There is also a lack of invest-
ment in scientific infrastructure and its maintenance.
Lack of technological capabilities in biological testing,
preclinical testing, formulation and standardization, and
related areas make it difficult to move from basic
research to applications. An analysis of the viability of
scaling up local pharmaceutical production has found
similar issues [12].
There is a lack of early stage proof of concept funding
and venture capital, which are essential to jump start
health and biotechnology product development. Nor are
there incentives for investments in R&D and its transla-
tion for the private sector.
Lack of coordination in research and its funding is
also a significant barrier to harnessing local health inno-
vation. All of those interviewed for this study identified
missing linkages between the science, business and capi-
tal providers as a significant barrier to knowledge flow
and translation between actors in the innovation system.
COSTECH, which is mandated with the implementation
of science policies along with research coordination and
its promotion, has been unable to fulfill all these roles
due to budgetary and infrastructure constraints. Despite
its vision to capture Tanzania’s innovation into socio-
economic benefits and poverty alleviation, COSTECH
has much ground to cover in terms of establishing lin-
kages with private sector and harnessing the country’s
research potential and biodiversity. This was highlighted
above in the case of value-added development of Tanza-
nia’s artemisinin locally. However, this seems to be
slowly changing; since our interviews, there has been a
change in management at COSTECH which has resulted
in it undergoing organizational reforms.
Numerous promising technologies have languished on
laboratory shelves without seeing the light of day. As
Dr Mwele Malachela, Director of Research and Coordi-
nation at NIMR points out “I think a lot of the gaps are
not real gaps but more about getting the linkages to
work. For me, a kind of center would be a good place to
have so these ideas are processed, so the visions of all
the stakeholders are taken into consideration. So I
would look at it from the point of view of the farmer,
researcher, down the line to the product, and then full
commercialization with private sector – [a] bringing
together of the ideas”. The scientific reform undertaken
by the ministry may begin to address this lack of
linkages.
In his key note address at a consultative workshop on
research capacity in Tanzania, the Hon. Dr Ali
Mohamed Shein, Vice President of the United Republic
of Tanzania, underlined that “The objective of research
is to find better ways of solving problems which people
face. It is, therefore, imperative that research findings
should reach end users, and in this case it is the people”
[18]. With an extensive science and technology system,
political will including the on going reform of its STI
system, and increase in R&D funds, Tanzania seems
well positioned for health research advances. Below are
recommendations which may help speed that process.
Recommendation 1: Consolidate groups and policies:
With its diverse S&T framework and numerous policies,
the government may wish to consolidate and synergize
groups and policies. For example, the Ministry of Health
and the Ministry of Communication, Science and Tech-
nology have extensive overlap in the coordination of the
health research agenda that could all be consolidated
under one ministry or agency like COSTECH.
Recommendation 2: Facilitate South-South collabora-
tion and diaspora linkages:. There already appear to be
partnerships between pharmaceutical firms in Tanzania
and those in India, China and Thailand. The govern-
emnt should provide greater mechanisms, funding and
channels to expand private sector partnership beyond
manufacturing to include innovation. Additionally it
should assist in establishing research partnership
between its extensive S&T research network and other
southern economies. Talented diaspora scientists and
businesspeople are also a resource to be tapped.
Recommendation 3: Increase investments in health and
biotechnology product development: Some of the recent
increase in scientific funding could support and encou-
rage proof of concept translational research. Providing
incentives to invest in R&D based businesses could
include tax breaks and credits for developing in house
R&D, stimulation of collaboration between science and
business, better infrastructure, easier access to raw
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material and equipment, and improved distribution net-
works. Donor agencies should consider moving towards
a model of funding that results in longer commitment
to health research areas, in combination with knowledge
translation and commercialization activities.
Recommendation 4: Create a mechanism to enhance
knowledge translation and linkages between business,
science and capital providers. Establishing an appropri-
ate innovation platform mechanism could stimulate
commercialization of Tanzanian health innovation. Such
platforms can tap Tanzania’s scientific potential in tradi-
tional medicine, diagnostics and clinical research by sys-
tematically evaluating the potential of existing R&D
through technology scouting and audits nationally.
Since the completion of our case study, we have con-
tinued to work with the Ministry of Communication,
Science and Technology to address some of the identi-
fied key challenges to commercialization of local health
research. We jointly hosted a national life sciences
workshop in December 2007 in Dar es Salaam where we
presented the case study results and recommendations,
which were discussed with local stakeholders, including
government officials, people working in the private sec-
tor, and members of the research community. Stake-
holders supported our results and recommendations
especially the need to increase knowledge flow. A local
steering committee has been formed for strategy and
planning to develop a life sciences innovation center
[19,20].
It is our hope that, through deeper understanding of
Tanzania’s current capabilities and future options, the
country can better realize its potential for science-based
health innovation.
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